According to Luyan Pharmaceutical's announcement, revenue for the first half of 2026 was 10.583 billion yuan, up 1.75% year on year; net profit attributable to shareholders of listed companies was 143 million yuan, down 7.46% year on year; after deducting non-net profit of 138 million yuan, down 9.88% year on year; net cash flow from operating activities was -101 million yuan, down 147.98% year on year. Furthermore, Chengdu Hechuang, a subsidiary of the company, was listed as the executee due to guarantee matters hidden by the original shareholders before the acquisition. The creditors have already received relevant payments during the execution of the case. Currently, the court has resumed execution of the case, and the company will push for the resolution of related matters.

According to Luyan Pharmaceutical's announcement, revenue for the first half of 2026 was 10.583 billion yuan, up 1.75% year on year; net profit attributable to shareholders of listed companies was 143 million yuan, down 7.46% year on year; after deducting non-net profit of 138 million yuan, down 9.88% year on year; net cash flow from operating activities was -101 million yuan, down 147.98% year on year. Furthermore, Chengdu Hechuang, a subsidiary of the company, was listed as the executee due to guarantee matters hidden by the original shareholders before the acquisition. The creditors have already received relevant payments during the execution of the case. Currently, the court has resumed execution of the case, and the company will push for the resolution of related matters.